{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:35:46Z","timestamp":1792460146437,"version":"4.5.0"},"reference-count":88,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Pompe disease (PD), a lysosomal storage disease, is caused by mutations of the GAA gene, inducing deficiency in the acid alpha-glucosidase (GAA). This enzymatic impairment causes glycogen burden in lysosomes and triggers cell malfunctions, especially in cardiac, smooth and skeletal muscle cells and motor neurons. To date, the only approved treatment available for PD is enzyme replacement therapy (ERT) consisting of intravenous administration of rhGAA. The limitations of ERT have motivated the investigation of new therapies. Pharmacological chaperone (PC) therapy aims at restoring enzymatic activity through protein stabilization by ligand binding. PCs are divided into two classes: active site-specific chaperones (ASSCs) and the non-inhibitory PCs. In this review, we summarize the different pharmacological chaperones reported against PD by specifying their PC class and activity. An emphasis is placed on the recent use of these chaperones in combination with ERT.<\/jats:p>","DOI":"10.3390\/molecules26237223","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T22:01:11Z","timestamp":1638309671000},"page":"7223","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacological Chaperone Therapy for Pompe Disease"],"prefix":"10.3390","volume":"26","author":[{"given":"Marc","family":"Borie-Guichot","sequence":"first","affiliation":[{"name":"SPCMIB, UMR5068 CNRS-Universit\u00e9 Paul Sabatier-Toulouse III, 118 Route de Narbonne, F-31062 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My Lan","family":"Tran","sequence":"additional","affiliation":[{"name":"SPCMIB, UMR5068 CNRS-Universit\u00e9 Paul Sabatier-Toulouse III, 118 Route de Narbonne, F-31062 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"G\u00e9nisson","sequence":"additional","affiliation":[{"name":"SPCMIB, UMR5068 CNRS-Universit\u00e9 Paul Sabatier-Toulouse III, 118 Route de Narbonne, F-31062 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-6188","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Ballereau","sequence":"additional","affiliation":[{"name":"SPCMIB, UMR5068 CNRS-Universit\u00e9 Paul Sabatier-Toulouse III, 118 Route de Narbonne, F-31062 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6313-7392","authenticated-orcid":false,"given":"C\u00e9cile","family":"Dehoux","sequence":"additional","affiliation":[{"name":"SPCMIB, UMR5068 CNRS-Universit\u00e9 Paul Sabatier-Toulouse III, 118 Route de Narbonne, F-31062 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"ref_1","first-page":"304","article-title":"Over idiopathische hypertrophie van het hart","volume":"76","author":"Pompe","year":"1932","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s12035-019-01820-5","article-title":"Molecular Approaches for the Treatment of Pompe Disease","volume":"57","author":"Bellotti","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.21037\/atm.2019.04.13","article-title":"Molecular genetics of Pompe disease: A comprehensive overview","volume":"7","author":"Peruzzo","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_4","unstructured":"(2021, July 07). Available online: Pompevariantdatabase.nl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajmg.a.35662","article-title":"How to describe the clinical spectrum in Pompe disease?","volume":"161A","author":"Gungor","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/8904_2015_426","article-title":"Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease","volume":"23","author":"Pena","year":"2015","journal-title":"JIMD Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/156802609787354306","article-title":"Design and Screening Strategies for alpha-Glucosidase Inhibitors Based on Enzymological Information","volume":"9","author":"Hakamata","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41467-017-01263-3","article-title":"Structure of human lysosomal acid alpha-glucosidase-a guide for the treatment of Pompe disease","volume":"8","author":"Iacono","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11458","DOI":"10.1016\/S0021-9258(18)60486-7","article-title":"The Cation-Dependent Mannose 6-Phosphate Receptor\u2014Structural Requirements for Mannose 6-Phosphate Binding and Oligomerization","volume":"264","author":"Dahms","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid alpha-glucosidase\u2014Major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","article-title":"Treatment of infantile Pompe disease with alglucosidase alpha: The UK experience","volume":"33","author":"Chakrapani","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe\u2019s Disease","volume":"362","author":"Clemens","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jimd.12272","article-title":"Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry","volume":"43","author":"Semplicini","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal Storage Diseases: From Pathophysiology to Therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: The Dutch experience in classic infantile Pompe disease","volume":"38","author":"Kroos","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_20","unstructured":"(2021, October 02). FDA Approves New Treatment for Pompe Disease, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-pompe-disease."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/hmg\/ddp535","article-title":"Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease","volume":"19","author":"Raben","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: Initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1038\/mtna.2014.57","article-title":"Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease","volume":"3","author":"Clayton","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1\u2013galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: A Review in Fabry Disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1021\/acschembio.6b00195","article-title":"Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases","volume":"11","author":"Convertino","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Liguori, L., Monticelli, M., Allocca, M., Mele, B.H., Lukas, J., Cubellis, M.V., and Andreotti, G. (2020). Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020489"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1039\/C7SC04712F","article-title":"Tuning protein folding in lysosomal storage diseases: The chemistry behind pharmacological chaperones","volume":"9","author":"Pereira","year":"2018","journal-title":"Chem. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1152\/physrev.00029.2016","article-title":"Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases","volume":"98","author":"Tao","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2014.01.005","article-title":"Pharmacological chaperoning: A primer on mechanism and pharmacology","volume":"83","author":"Leidenheimer","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/BC.2008.009","article-title":"A counterintuitive approach to treat enzyme deficiencies: Use of enzyme inhibitors for restoring mutant enzyme activity","volume":"389","author":"Fan","year":"2008","journal-title":"Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tran, M.L., Genisson, Y., Ballereau, S., and Dehoux, C. (2020). Second-Generation Pharmacological Chaperones: Beyond Inhibitors. Molecules, 25.","DOI":"10.3390\/molecules25143145"},{"key":"ref_34","first-page":"997","article-title":"An Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic Naive Rheumatoid Arthritis Patients","volume":"67","author":"Kottak","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders","volume":"9","author":"Valenzano","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9462","DOI":"10.1021\/acs.jmedchem.7b00646","article-title":"N-Butyl-L-deoxynojirimycin (L-NBDNJ): Synthesis of an Allosteric Enhancer of alpha-Glucosidase Activity for the Treatment of Pompe Disease","volume":"60","author":"Porto","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Khanna, R., Flanagan, J.J., Feng, J., Soska, R., Frascella, M., Pellegrino, L.J., Lun, Y., Guillen, D., Lockhart, D.J., and Valenzano, K.J. (2012). The pharmacological chaperone AT2220 increases recombinant human acid \u03b1-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040776"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/mt.2015.87","article-title":"Coformulation of a Novel Human \u03b1-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice","volume":"23","author":"Xu","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbrc.2008.02.125","article-title":"Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase","volume":"369","author":"Shen","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/cmdc.201700216","article-title":"Recent Advances in Synthetic alpha-Glucosidase Inhibitors","volume":"12","author":"Liu","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Compain, P., and Martin, O.R. (2007). Iminosugars: From Synthesis to Therapeutic Applications, Wiley.","DOI":"10.1002\/9780470517437"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"108317","DOI":"10.1016\/j.carres.2021.108317","article-title":"An overview of therapeutic potential of N-alkylated 1-deoxynojirimycin congeners","volume":"504","author":"Iftikhar","year":"2021","journal-title":"Carbohydr. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1517\/14656566.1.1.149","article-title":"Miglitol, a new alpha-glucosidase inhibitor","volume":"1","author":"Sels","year":"1999","journal-title":"Expert Opin Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bcp.2003.09.036","article-title":"Inhibition of glycogen breakdown by imino sugars in vitro and in vivo","volume":"67","author":"Andersson","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1016\/j.bmc.2006.08.003","article-title":"alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease","volume":"14","author":"Yu","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher Disease-Associated Glucocerebrosidases Show Mutation-Dependent Chemical Chaperoning Profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cbic.201200005","article-title":"Cyclodextrin-based iminosugar click clusters: The first examples of multivalent pharmacological chaperones for the treatment of lysosomal storage disorders","volume":"13","author":"Decroocq","year":"2012","journal-title":"ChemBioChem"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mt.6300074","article-title":"Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease","volume":"15","author":"Parenti","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2006.09.010","article-title":"Chemical chaperones improve transport and enhance stability of mutant \u03b1-glucosidases in glycogen storage disease type II","volume":"90","author":"Okumiya","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.febslet.2006.06.096","article-title":"Stabilizing normal and mis-sense variant \u03b1-glucosidase","volume":"580","author":"Kakavanos","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_53","unstructured":"Xiao, J., Marugan, J.J., Zheng, W., Motabar, O., Southall, N., Goldin, E., Sidransky, E., Liu, K., Ferrer, M., and Austin, C.P. (2010). 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one Analogs as Inhibitors of Acid alpha-Glucosidase for Potential Chaperone Treatment of Pompe Disease or Intervention for Diabetes Mellitus Type 2, Probe Reports from the NIH Molecular Libraries Program."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1021\/jm3005543","article-title":"Discovery of a Novel Noniminosugar Acid alpha Glucosidase Chaperone Series","volume":"55","author":"Xiao","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/cbic.200600217","article-title":"Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher\u2019s disease","volume":"7","author":"Compain","year":"2006","journal-title":"ChemBioChem"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological Enhancement of alpha-Glucosidase by the Allosteric Chaperone N-acetylcysteine","volume":"20","author":"Porto","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_57","unstructured":"Parenti, G., Porto, C., Moracci, M., Ferrara, M.C., Cobucci-Ponzano, B., and Andria, G. (2013). Allosteric Non-Inhibitory Chaperones of Lysosomal Acid \u03b1-Glucosidase and Uses Thereof. (WO2013182652), U.S. Patent."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1080\/14756366.2021.1975694","article-title":"Carnitine is a pharmacological allosteric chaperone of the human lysosomal \u03b1-glucosidase","volume":"36","author":"Iacono","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ejmech.2010.01.027","article-title":"Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido 4,5-d pyrimidin-4(1H)-one analogues as GAA activators","volume":"45","author":"Marugan","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_60","unstructured":"Marugan, J.J., Zheng, W., Ferrer, M., Motabar, O., Southall, N., Goldin, E., Westbroek, W., and Sidransky, E. (2010). Discovery, SAR, and Biological Evaluation of a Non-Inhibitory Chaperone for Acid Alpha Glucosidase, Probe Reports from the NIH Molecular Libraries Program."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Khanna, R., Powe, A.C., Lun, Y., Soska, R., Feng, J., Dhulipala, R., Frascella, M., Garcia, A., Pellegrino, L.J., and Xu, S. (2014). The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102092"},{"key":"ref_63","unstructured":"(2021, September 15). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02675465?term=atb200."},{"key":"ref_64","unstructured":"(2021, September 15). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03729362."},{"key":"ref_65","unstructured":"(2021, October 10). U.S. FDA Accepts Filings for Amicus\u2019 AT-GAA for the Treatment of Pompe Disease. Available online: https:\/\/ir.amicusrx.com\/news-releases\/news-release-details\/us-fda-accepts-filings-amicus-gaa-treatment-pompe-disease."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ymthe.2017.02.017","article-title":"Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid \u03b1-Glucosidase in Pompe Patients Co-administered with Alglucosidase \u03b1","volume":"25","author":"Kishnani","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.tetasy.2004.11.067","article-title":"The L-enantiomers of D-sugar-mimicking iminosugars are noncompetitive inhibitors of D-glycohydrolase?","volume":"16","author":"Asano","year":"2005","journal-title":"Tetrahedron Asymmetry"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Yu, C.Y., Asano, N., Ikeda, K., Wang, M.X., Butters, T.D., Wormald, M.R., Dwek, R.A., Winters, A.L., Nash, R.J., and Fleet, G.W. (2004). Looking glass inhibitors: L-DMDP, a more potent and specific inhibitor of alpha-glucosidases than the enantiomeric natural product DMDP. Chem. Commun., 1936\u20131937.","DOI":"10.1039\/B406035K"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tetlet.2010.10.173","article-title":"4-C-Me-DAB and 4-C-Me-LAB\u2014Enantiomeric alkyl-branched pyrrolidine iminosugars\u2014Are specific and potent alpha-glucosidase inhibitors; acetone as the sole protecting group","volume":"52","author":"Newberry","year":"2011","journal-title":"Tetrahedron Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1016\/j.bmc.2008.01.032","article-title":"Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases","volume":"16","author":"Minami","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1021\/ol201552q","article-title":"Looking-glass synergistic pharmacological chaperones: DGJ and L-DGJ from the enantiomers of tagatose","volume":"13","author":"Jenkinson","year":"2011","journal-title":"Org. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1039\/D0OB01522A","article-title":"Concise asymmetric synthesis of new enantiomeric C-alkyl pyrrolidines acting as pharmacological chaperones against Gaucher disease","volume":"18","author":"Castellan","year":"2020","journal-title":"Org. Biomol. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cmdc.200800350","article-title":"Design, Synthesis, and Biological Evaluation of Enantiomeric beta-N-Acetylhexosaminidase Inhibitors LABNAc and DABNAc as Potential Agents against Tay-Sachs and Sandhoff Disease","volume":"4","author":"Rountree","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1016\/j.bmc.2008.06.026","article-title":"In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures","volume":"16","author":"Kuriyama","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/cmdc.201402023","article-title":"Glucocerebrosidase Enhancers for Selected Gaucher Disease Genotypes by Modification of alpha-1-C-Substituted Imino-D-xylitols (DIXs) by Click Chemistry","volume":"9","author":"Diaz","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/cmdc.201200309","article-title":"Systematic Structure-Activity Study on Potential Chaperone Lead Compounds for Acid alpha-Glucosidase","volume":"7","author":"Bruckmann","year":"2012","journal-title":"Chemmedchem"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Kato, A., Nakagome, I., Hata, M., Nash, R.J., Fleet, G.W.J., Natori, Y., Yoshimura, Y., Adachi, I., and Hirono, S. (2020). Strategy for Designing Selective Lysosomal Acid alpha-Glucosidase Inhibitors: Binding Orientation and Influence on Selectivity. Molecules, 25.","DOI":"10.3390\/molecules25122843"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/S0040-4039(00)98636-2","article-title":"Potent Competitive-Inhibition of Alpha-Galactosidase and Alpha-Glucosidase Activity by 1,4-Dideoxy-1,4-Iminopentitols\u2014Syntheses of 1,4-Dideoxy-1,4-Imino-D-Lyxitol and of Both Enantiomers of 1,4-Dideoxy-1,4-Iminoarabinitol","volume":"26","author":"Fleet","year":"1985","journal-title":"Tetrahedron Lett."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0024-3205(86)90046-9","article-title":"Inhibiton of Mammalian Digestive Disaccharidases by Polyhydroxy Alkaloids","volume":"39","author":"Scofield","year":"1986","journal-title":"Life Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1016\/S0040-4020(01)88174-6","article-title":"The Synthesis from D-Xylose of the Potent and Specific Enantiomeric Glucosidase Inhibitors, 1,4-Dideoxy-1,4-Imino-D-Arabinitol and 1,4-Dideoxy-1,4-Imino-L-Arabinitol","volume":"42","author":"Fleet","year":"1986","journal-title":"Tetrahedron"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1016\/S0040-4020(01)90163-2","article-title":"Synthesis from D-Lyxonolactone of 1,4-Dideoxy-1,4-Imino-L-Arabinitol, a Glucosidase Inhibitor with Invitro Antiviral Activity","volume":"49","author":"Behling","year":"1993","journal-title":"Tetrahedron"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mt.2014.224","article-title":"Enzyme enhancers for the treatment of Fabry and Pompe disease","volume":"23","author":"Lukas","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_84","unstructured":"Lukas, J., Pews-Davtyan, A., Beller, M., and Rolfs, A. (2013). Combination of Imino-Sugar Pharmacological Chaperons Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and\/or a Derivatives of Ambroxol for Treatment of Lysosomal Storage Diseases. (WO2013091897), U.S. Patent."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"43R","DOI":"10.1093\/glycob\/cwi076","article-title":"Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses","volume":"15","author":"Butters","year":"2005","journal-title":"Glycobiology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ab.2009.04.010","article-title":"A new resorufin-based alpha-glucosidase assay for high-throughput screening","volume":"390","author":"Motabar","year":"2009","journal-title":"Anal. Biochem."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Stepien, K.M., Roncaroli, F., Turton, N., Hendriksz, C.J., Roberts, M., Heaton, R.A., and Hargreaves, I. (2020). Mechanisms of Mitochondrial Dysfunction in Lysosomal Storage Disorders: A Review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082596"},{"key":"ref_88","unstructured":"Mendlein, J. (2020). mRNA based Enzyme Replacement Therapy Combined with A Pharmacological Chaperone for the Treatment of Lysosomal Storage Disorders. (WO2020023390), U.S. Patent."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/23\/7223\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:37:09Z","timestamp":1760168229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/23\/7223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":88,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["molecules26237223"],"URL":"https:\/\/doi.org\/10.3390\/molecules26237223","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]}}}